Status:
NOT_YET_RECRUITING
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Amyloidosis, Hereditary
Eligibility:
All Genders
18+ years
Brief Summary
The study design is a prospective registry including asymptomatic and symptomatic patients who carry a pathogenic TTR mutation. The study will enroll patients who meet the inclusion criteria and none ...
Detailed Description
Hereditary transthyretin amyloidosis (hATTR) is an autosomal dominant disorder caused by a pathogenic mutation of the transthyretin (TTR) gene. The mutated gene destabilizes the TTR tetramer causing i...
Eligibility Criteria
Inclusion
- Over the age of 18 years
- Carrier of a pathogenic hATTR mutation confirmed on whole blood gene testing or mass spectrometry
- Willing to return for required follow-up visits
Exclusion
- Patient having undergone heart transplantation or implantation of mechanical circulatory support
- Patients unable to provide informed consent
- Patients having undergone liver transplantation
- Patients have evidence of light chain amyloidosis
Key Trial Info
Start Date :
February 1 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05974644
Start Date
February 1 2026
End Date
December 1 2030
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298